A case in point: it turns out that only about half of the new prescription medications pushed onto the market over the last decade had the proper data together for the U.S. Food and Drug Administration - yet the FDA approved them anyhow.
The researchers found that only about half of 197 eligible approved NMEs between 2000 and 2010 had comparative efficacy data available at the time they were approved to be marketed.
Meanwhile, another recent study throws needed light on the limited data behind the safety and effectiveness of some Big Pharma drugs.
Since September, 16 major drug companies have inked deals with the Trump administration to lower prices....
